Low-Dose Oral Minoxidil Initiation for Patients With Hair Loss

    November 2024 in “ JAMA Dermatology
    Yagiz Matthew Akiska, Paradi Mirmirani, Ingrid Roseborough, Erin F. Mathes, Tina Bhutani, Andrew P. Ambrosy, Crystal Aguh, Wilma F. Bergfeld, Valerie Callender, Leslie Castelo‐Soccio, George Cotsarelis, Brittany G. Craiglow, Nisha S. Desai, Isabella Doche, Bruna Duque‐Estrada, Dirk M. Elston, Carolyn Goh, Lynne J. Goldberg, Ramón Grimalt, Ali Jabbari, Victoria Jolliffe, Brett King, Charlotte LaSenna, Yolanda M. Lenzy, Jenna Lester, Nino Lortkipanidze, Kristen I. Lo Sicco, Amy McMichael, Nekma Meah, Natasha Atanaskova Mesinkovska, Mariya Miteva, Arash Mostaghimi, Yuliya Ovcharenko, Melissa Piliang, Bianca Maria Piraccini, Adriana Rakowska, Kimberly Salkey, Adriana N. Schmidt, Jerry Shapiro, Cathryn Sibbald, Rodney Sinclair, Poonkiat Suchonwanit, Susan S. Taylor, Antonellá Tosti, Sergio Vañó‐Galván, Dmitri Wall, Jennifer M. Fu
    Image of study
    TLDR Low-dose oral minoxidil may help with hair loss, but more research is needed.
    A recent international consensus statement involving 43 hair loss specialist dermatologists from 12 countries has provided guidance on the off-label use of low-dose oral minoxidil (LDOM) for treating hair loss. The consensus, reached through a modified Delphi process, covers 76 items including diagnoses, indications for LDOM over topical minoxidil, dosing for adults and adolescents, contraindications, and monitoring. While LDOM is gaining popularity as a treatment, the statement highlights the need for more high-quality evidence and research, particularly regarding pediatric use, long-term safety, and comparisons with topical minoxidil. The findings aim to inform clinical practice until more comprehensive data are available.
    Discuss this study in the Community →

    Research cited in this study

    22 / 22 results

    Related Community Posts Join

    6 / 1000+ results

    Related Research

    9 / 9 results